Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Safety and Efficacy of SYD-101 in Children With Myopia
NCT03918915 · View on ClinicalTrials.gov ↗
Study Summary
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SYD-101 0.01%
- DRUG SYD-101 0.03%
Study Locations (20)
California
- Site 143 — Irwindale
- Site 144 — Pasadena
- Site 148 — San Diego
- Site 104 — San Diego
- Site 110 — Santa Barbara
- Site 133 — Sunnyvale
Florida
- Site 122 — Fort Lauderdale
- Site 109 — Jupiter
- Site 119 — Sweetwater
- Site 120 — Tamarac
Colorado
- Site 130 — Colorado Springs
- Site 100 — Fort Collins
Connecticut
- Site 102 — Danbury
- Site 150 — Waterbury
Illinois
- Site 116 — Chicago
- Site 106 — Wilmette
Indiana
- Site 135 — Indianapolis
- Site 131 — Munster
Georgia
- Site 124 — Marietta
Kansas
- Site 137 — Pittsburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918915
The ClinicalTrials.gov registry entry for NCT03918915 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 852 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sydnexis, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Nearsightedness appearing as the primary indexed condition, and to 3 interventions — of which Vehicle is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03918915 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03918915 about?
NCT03918915 is a clinical study titled "The Safety and Efficacy of SYD-101 in Children With Myopia". Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Earl...
What is the current status of trial NCT03918915?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2019-04-24. Estimated completion is 2025-05-01.
What conditions does trial NCT03918915 study?
This clinical trial studies the following conditions: Nearsightedness, Near Sightedness, Near-sightedness. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03918915?
The interventions under investigation include: Vehicle (DRUG), SYD-101 0.01% (DRUG), SYD-101 0.03% (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03918915?
This trial is sponsored by Sydnexis, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03918915 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.